July 29 (Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration issued "certain observations" after an inspection of the company's manufacturing plant in Taiwan.
(Reuters) - Shares of Impax Laboratories Inc fell as much as 10 percent on Tuesday, after U.S. health regulators denied approval to the company's Parkinson's drug and asked for a reinspection of its...
(Reuters) - Impax Laboratories Inc said it received a warning letter from U.S. health regulators on deficient sampling and testing of drugs at its Hayward, California-based plant, sending the...
competition until late 2011, thanks to several deals with Teva TEVA, Sandoz (a unit of Novartis NVS), Mylan MYL, and Impax IPXL . By paying the generic companies to delay competition, Medicis has lengthened the runway for Solodyn. The firm may have bought
We are no longer providing equity research on Impax Labs IPXL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
and expect to make a significant cut to our fair value estimate. Medicis had previously reached an agreement with Impax Labs IPXL (the first to file for approval) to delay the launch of its Solodyn generic until late 2011, but that may not hold if other
Monday that it has settled all outstanding patent disputes over its acne drug Solodyn with generic drug maker Impax Laboratories . Under the agreement, Medicis will pay Impax $40 million up front in return for Impax working in partnership
Medicis Pharmaceuticals MRX announced Jan. 15 that it received a formal patent challenge from Impax Laboratories IPXL concerning its Solodyn acne drug. We expect Solodyn to generate sales of about $200 million in 2007, or 44% of Medicis' total
Medicis Pharmaceuticals MRX announced Tuesday that it has received a formal patent challenge from Impax Laboratories IPXL concerning its Solodyn acne drug. We expect Solodyn to generate sales of about $200 million in 2007, or 44
Endo Pharmaceuticals ENDP announced Wednesday that it has received a formal patent challenge from Impax Laboratories concerning its Opana ER pain drug. We expect Opana ER to generate sales of roughly $100 million in 2007, or about 10% of Endo